Hana Biosciences News
Most Popular Hana Biosciences Story
ALSO NOTED: Neuren buys Hamilton Pharma; Merck pulls out of MethyGene collaboration; Par licenses Zensana rights; and much more
> New Zealand's Neuren is acquiring Washington D.C.-based Hamilton Pharmaceuticals for $4.4 million in a deal that delivers the license for a drug called Motiva, a late-stage preclinical compound Read more...
Latest Headlines
- April 30, 2008
- October 31, 2007
- August 29, 2007
- August 29, 2006
- May 21, 2006
- March 29, 2006
- March 16, 2006
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
